Concord Biotech Ltd. Share Price

Concord Biotech Approves 1:1 Bonus Issue

Concord Biotech has approved its first-ever 1:1 bonus issue, subject to shareholder approval. Under the proposal, eligible shareholders will receive one additional fully paid-up equity share of ₹1 each for every one existing share held on the record date. The record date will be announced separately by the company’s board. Alongside the bonus issue, Concord Biotech has approved an increase in its authorised share capital from ₹11 crore to ₹22 crore by creating 11 crore additional equity shares. The bonus shares will be issued by capitalising the company’s share premium account, which stood at ₹81.97 crore as of March 31, 2026. The move will increase the company’s paid-up equity share count while maintaining the same proportionate ownership of existing shareholders. Concord Biotech’s board approved the corporate action on September 23, 2026. Disclaimer: The views expressed purely for educational and informational purposes and do not constitute financial advice or a recommendation to buy, sell, or hold any security

See More

Concord Biotech Approves 1:1 Bonus Issue

Concord Biotech Limited

has approved its maiden 1:1 bonus share issue, alongside raising authorised share capital to Rs 22 crore from Rs 11 crore. The decision follows a USFDA inspection at its Unit II Valthera facility that closed with only one minor procedural observation. Paid up share capital will rise from Rs 10.46 crore to Rs 20.92 crore after the bonus allotment, doubling the outstanding share count. The USFDA audit at Valthera concluded on September 18, 2026, with just one minor procedural observation, a clean outcome for an export-facing facility. In Q1 FY27, consolidated revenue grew 26% year on year to Rs 257.5 crore, net profit rose 31% to Rs 57.7 crore, and EBITDA rose 34% to Rs 82.4 crore, a 32% operating margin. API revenue grew 42% to Rs 218.9 crore, while formulation revenue fell 23% to Rs 38.6 crore. The bonus issue itself does not change underlying value, it is a non-cash action that simply splits existing equity into more shares. The bigger swing factor in the numbers is the split within Q1 FY27 itself, API revenue up 42% against formulation revenue down 23%, which tells you the API business, the higher margin, higher barrier segment, is carrying the quarter while formulations remains inconsistent. I am watching shareholder approval of the bonus and capital increase at the EGM, the formal USFDA clearance letter for Valthera, and whether formulation revenue stabilises in Q2 FY27. This is a shareholder-friendly action backed by genuinely strong API-led earnings, though formulation volatility is worth tracking separately. I am watching over a 3 to 12 month horizon through EGM approval. Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations.

See More

Symbiotec Pharmalab posts 7% revenue growth, profit halves

Symbiotec Pharmalab Limited [

] reported a 7 percent year-on-year growth in consolidated revenue for Q1 FY27. Net profit nearly halved during the quarter due to rising operational expenses and higher depreciation linked to new growth initiatives. The sharp drop in net profit reflects execution costs rather than weakness in core operations. While gross margins expanded to 65 percent from 62 percent in Q1 FY26, EBITDA margins compressed to 21 percent from 28 percent. The company is actively investing in double chamber technology for complex injectables and expanding its bio-CDMO capacity. Headline profit numbers mask the structural transition underway. Over 56 percent of the company's total capex of Rs 1,475 crore is allocated to new growth engines, which are yet to generate full revenue. Commercialisation of key double-chamber vial products and long-term take-or-pay agreements in the CDMO space offer strong revenue visibility. With legacy API facilities operating at high capacity and the stock trading at a valuation discount to peers like Concord Biotech and Laurus Labs, the margin pressure appears temporary. Investors should track the commercial execution of double-chamber vial products scheduled for FY28, regulatory approvals in the US market, and margin recovery over the next two to four quarters. For long-term investors, accumulating the stock on dips presents a favorable risk-reward opportunity.

See More

Concord Biotech Delivers Strong Q1FY26 Earnings Growth

💊

reported a 43.7% year-on-year increase in consolidated net profit to ₹57.7 crore for Q1FY26. Revenue from operations rose 26.2% to ₹257.5 crore, reflecting strong business momentum and healthy operational performance.

See More

Update for investors of

is currently trading at Rs. 1340.60, up by 24.05 points or 1.83% from its previous closing of Rs. 1316.55 on the BSE. The scrip opened at Rs. 1316.55 and has touched a high and low of Rs. 1377.95 and Rs. 1316.50 respectively. So far 22084 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 2024.10 on 20-Jun-2025 and a 52 week low of Rs. 987.05 on 02-Apr-2026. Last one week high and low of the scrip stood at Rs. 1408.15 and Rs. 1306.00 respectively. The current market cap of the company is Rs. 13978.82 crore. The promoters holding in the company stood at 44.08%, while Institutions and Non-Institutions held 17.02% and 38.90% respectively. Concord Biotech has entered into an agreement to acquire 27.38% stake in M/s FSGE Renewable Power (FSGE) for a consideration of Rs 6.3 crore. The investment is for installation of Wind Solar Hybrid Power Project having a Wind Capacity of around 6.3 MW AC & Solar Capacity of around 6.3 MWp DC in Gujarat for Limbasi Facility of the company. The investment aligns with the company’s commitment to sustainability and its focused efforts to address environmental challenges. FSGE is a Special Purpose Vehicle incorporated for the purpose of developing a captive power generation facility for the company and it has not commenced its operations. By transitioning to renewable energy sources, the company will reduce its carbon footprint, contributing to global efforts to combat climate change. Additionally, renewable energy offers long-term financial benefits, including reduction in energy costs. This strategic investment reinforces the company’s commitment to environmental responsibility and supporting sustainable growth while enhancing operational efficiency. Concord Biotech is an India-based biopharma company and one of the leading global developers and manufacturers of select fermentation-based APIs across Immunosuppressants and oncology.

See More